Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
0.5015
-0.0395 (-7.30%)
At close: Aug 14, 2026, 4:00 PM EDT
0.6259
+0.1244 (24.81%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Skye Bioscience Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 8.15 | 5.88 | 68.42 | 1.26 | 1.24 | 8.98 |
Short-Term Investments | 8.96 | 19.85 | - | - | 0.07 | - |
Cash & Short-Term Investments | 17.11 | 25.74 | 68.42 | 1.26 | 1.32 | 8.98 |
Cash Growth | -71.11% | -62.38% | 5345.15% | -4.72% | -85.32% | 263.77% |
Other Receivables | 0.01 | 0.01 | 0.01 | 0.7 | 0.18 | - |
Receivables | 0.01 | 0.01 | 0.01 | 0.7 | 0.18 | - |
Prepaid Expenses | 1.22 | 0.5 | 0.2 | 0.19 | 0.78 | 0.57 |
Restricted Cash | - | - | - | 9.08 | 0 | 0 |
Other Current Assets | 0.23 | 0.84 | 2.2 | 0.42 | 6.66 | 0.06 |
Total Current Assets | 18.57 | 27.09 | 70.83 | 11.65 | 8.94 | 9.61 |
Property, Plant & Equipment | 0.81 | 1.17 | 1.88 | 0.28 | 0.16 | 0.23 |
Other Long-Term Assets | 0.04 | 0.05 | 0.05 | 0.01 | 0.01 | 0.01 |
Total Assets | 19.42 | 28.31 | 72.76 | 11.94 | 9.11 | 9.86 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.94 | 2.03 | 0.57 | 0.96 | 1.79 | 0.9 |
Accrued Expenses | 3.58 | 3.91 | 1.77 | 2.06 | 1.12 | 0.9 |
Short-Term Debt | 0.25 | - | - | 4.37 | 0.06 | - |
Current Portion of Long-Term Debt | - | - | - | - | 1.85 | 1.97 |
Current Portion of Leases | 0.06 | 0.19 | 0.18 | 0.07 | 0.08 | 0.08 |
Other Current Liabilities | 2.57 | 2.07 | 1.82 | 6.44 | 7.22 | 0.06 |
Total Current Liabilities | 10.4 | 8.21 | 4.34 | 13.9 | 12.12 | 3.91 |
Long-Term Leases | - | 0.08 | 0.27 | 0.17 | - | 0.08 |
Total Liabilities | 10.4 | 8.29 | 4.61 | 14.07 | 12.12 | 3.99 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.04 | 0.03 | 0.03 | 0.01 | 0 | 0.48 |
Additional Paid-In Capital | 208.36 | 206.87 | 199.07 | 102.24 | 63.73 | 52.64 |
Retained Earnings | -199.38 | -186.87 | -130.95 | -104.38 | -66.74 | -47.26 |
Total Common Equity | 9.01 | 20.02 | 68.15 | -2.13 | -3.01 | 5.86 |
Shareholders' Equity | 9.01 | 20.02 | 68.15 | -2.13 | -3.01 | 5.86 |
Total Liabilities & Equity | 19.42 | 28.31 | 72.76 | 11.94 | 9.11 | 9.86 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.31 | 0.27 | 0.46 | 4.62 | 1.98 | 2.14 |
Net Cash (Debt) | 16.8 | 25.46 | 67.96 | -3.36 | -0.66 | 6.85 |
Net Cash Growth | -71.44% | -62.53% | - | - | - | 604.71% |
Net Cash Per Share | 0.42 | 0.64 | 1.86 | -0.48 | -0.30 | 4.21 |
Filing Date Shares Outstanding | 35.14 | 33.38 | 30.97 | 28.06 | 3.89 | 1.98 |
Total Common Shares Outstanding | 35.13 | 33.38 | 30.97 | 12.35 | 3.65 | 1.9 |
Working Capital | 8.16 | 18.89 | 66.49 | -2.25 | -3.18 | 5.7 |
Book Value Per Share | 0.26 | 0.60 | 2.20 | -0.17 | -0.82 | 3.08 |
Tangible Book Value | 9.01 | 20.02 | 68.15 | -2.13 | -3.01 | 5.86 |
Tangible Book Value Per Share | 0.26 | 0.60 | 2.20 | -0.17 | -0.82 | 3.08 |
Machinery | - | 1.65 | 1.64 | 0.12 | - | - |
Leasehold Improvements | - | 0.02 | 0.02 | 0.01 | - | - |